$LLY (Eli Lilly and Company)

$LLY {{ '2015-10-22T12:13:05+0000' | timeago}} • Announcement

$LLY's revenue by product had mixed results YoverY as Forteo, Strattera, Trajenta, and Animal Health revenues increased YoverY while Alimta, Humulin, Cymbalta, Zyprexa, and Evista reported declines in revenue; Evista declined significantly by 35%. On a YoverY basis, Humalog, Cialis, and Effient reported flat revenues compared to last year.

$LLY {{ '2017-07-25T15:33:57+0000' | timeago}} • Announcement

$LLY and its development and marketing partner $INCY announced that resubmission of rheumatoid arthritis drug baricitinib will be delayed beyond 2017 and at least it will take 18 months. FDA has demanded for a new trial. ELi Lilly added that baricitinib tablets have been approved since Feb 2017 in EU and the drug was approved recently in Japan.

$LLY {{ '2017-07-25T14:13:17+0000' | timeago}} • Announcement

$LLY, which joined hands with $NKTR recently to co-develop the autoimmune drug NKTR-358, cut down its GAAP earnings outlook for FY17 by $0.09 per share to $2.51-2.61. However, Eli Lilly lifted its non-GAAP EPS estimate to $4.10-4.20 from the prior outlook of $4.05-4.15 Revenue outlook also lifted to $22.0-22.5Bil from prior range of $21.8-22.3Bil.

$LLY {{ '2017-07-25T13:14:16+0000' | timeago}} • Announcement

Drugmaker $LLY reported a jump in its profit for the second quarter 2017, boosted by new pharma products sales and higher realized prices. Profit climbed 35% to $1.01Bil and GAAP EPS surged 34% to $0.91 versus a year ago. Revenue grew 8% to $5.82Bil and non-GAAP EPS spiked up 29% to $1.11.

$LLY {{ '2017-07-25T12:32:52+0000' | timeago}} • Infographic

$LLY Eli Lilly and Company Earnings AlphaGraphic: Q2 2017 Highlights

$LLY {{ '2017-07-24T19:31:07+0000' | timeago}} • Announcement

As a result of the deal signed with Nektar on co-developing autoimmune drug NKTR-358, $LLY expects a charge of about $0.09 per share to its 2017 earnings. Eli Lilly cut down its 2017 GAAP EPS outlook by $0.09 to $2.51-2.61 from its previous outlook of $2.60-2.70 and it didn't change the estimate for non-GAAP EPS because of the Nektar partnership.

$LLY {{ '2017-07-24T18:19:30+0000' | timeago}} • Announcement

$LLY to co-develop $NKTR's autoimmune drug NKTR-358. Under the deal terms, Eli Lilly will pay Nektar Therapeutics an upfront payment of $150MM and up to $250MM if development and regulatory milestones are achieved. Nektar to complete Phase 1 clinical development and will bear 25% of Phase 2 cost. $LLY will bear 75% of the Phase 2 development cost.

$LLY {{ '2017-07-12T14:48:02+0000' | timeago}} • Announcement

$LLY said that the patent expiration for Adcirca, a drug to treat blood pressure in lungs, is still expected on Nov 21, 2017, or on May 21, 2018, if the FDA approves the company's application for pediatric exclusivity.

$LLY {{ '2017-07-12T14:47:24+0000' | timeago}} • Announcement

$LLY said that its FY17 financial guidance is unaffected and there will be no change in the mid-term expectations through the remainder of the decade due to the settlement agreement in connection with the patent litigation for its erectile dysfunction drug Cialis.

$LLY {{ '2017-07-12T14:46:07+0000' | timeago}} • Announcement

$LLY reaches an agreement with generic companies with regard to the patent litigation for its erectile dysfunction drug Cialis. The patent, which is expected to expire previously on April 26, 2020, is now expected to end 1.5 years earlier (at the earliest on Sept 27, 2018).

$LLY {{ '2017-07-10T12:28:13+0000' | timeago}} • Announcement

Healthcare firm $LLY said TV entertainer Don Francisco has partnered with Lilly and Boehringer Ingelheim to launch an awareness initiative titled Basado en Hechos, to address common misconceptions about type-2 diabetes and insulin treatment. Francisco will visit cities across the country to share his personal journey of ‘living with diabetes’.

$LLY {{ '2017-07-10T11:40:23+0000' | timeago}} • Announcement

$LLY said the FDA has accepted and filed its New Drug Application (NDA) for abemaciclib, a cyclin-dependent kinase (CDK)4 & 6 inhibitor, to treat advanced breast cancer, and given the NDA a Priority Review designation. $LLY plans to submit abemaciclib to European regulators in 3Q17 and to Japanese regulators before the end of 2017.

$LLY {{ '2017-07-07T12:11:45+0000' | timeago}} • Announcement

The UK Supreme Court favors the Indianapolis-based drugmaker $LLY in the litigation against Actavis related to its cancer drug Alimta. The Court said that Actavis' products directly infringe Lilly's vitamin regimen patents in the UK, France, Italy and Spain.

$LLY {{ '2017-07-06T13:03:00+0000' | timeago}} • Announcement

$LLY and Purdue University announced a strategic collaboration to conduct life science research. The five-year agreement, where $LLY will provide up to $52MM, marks Purdue's largest strategic collaboration with a single company.

$LLY {{ '2017-06-21T15:15:02+0000' | timeago}} • Announcement

$LLY announced completion of a $90MM expansion of its Biotechnology Center in San Diego, California. $LLY's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain.

$LLY {{ '2017-06-19T18:52:56+0000' | timeago}} • Announcement

$LLY BoD declared a dividend of $0.52 per share on outstanding common stock for 3Q17. The dividend is payable Sept. 8, 2017, to shareholders of record at the close of business on Aug. 15, 2017.

$LLY {{ '2017-06-15T15:01:12+0000' | timeago}} • Announcement

$LLY said patients with active psoriatic arthritis who treated with Taltz (ixekizumab) achieved significant improvement in signs and symptoms of their disease at 24 weeks when compared to placebo. Psoriatic arthritis is a chronic, progressive disease that can cause pain, swelling and stiffness of the joints.

$LLY {{ '2017-06-14T08:45:38+0000' | timeago}} • Announcement

Pharma firms $LLY and $INCY will present data from studies conducted on Olumiant, indicated for inflammatory and autoimmune diseases, at the Annual European Congress of Rheumatology being held in Madrid from June 14 to 17, 2017. Six abstracts evaluating Taltz, indicated for the treatment of psoriatic arthritis, will also be presented at the meet.

$LLY {{ '2017-06-13T19:20:27+0000' | timeago}} • Announcement

The US FDA approved $LLY’s Humalog Junior KwikPen for the treatment of diabetes. Humalog Junior KwikPen is a prefilled pen with half-unit dosing capability, enabling finer dose adjustment for those who need it. Humalog Junior KwikPen will be available in US pharmacies later in 2017.

$PFE {{ '2017-06-13T15:05:11+0000' | timeago}} • Announcement

Pharma firms $PFE and $LLY have received fast track designation from the FDA for tanezumab, an antibody against nerve growth factor. If approved, Tanezumab would be the first in the new class of non-opioid chronic medications. Meanwhile, results of an ongoing phase-3 clinical development program for tanezumab are projected to start coming in 2018.

$PFE {{ '2017-06-13T14:51:52+0000' | timeago}} • Announcement

$PFE and $LLY said that the FDA has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP). Tanezumab is an investigational humanized monoclonal antibody that selectively targets, binds to and inhibits nerve growth factor (NGF).

Recent Transcripts

BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
MMSI (Merit Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
CNMD (CONMED Corporation)
Wednesday, July 26 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
BABY (Natus Medical Inc.)
Wednesday, July 26 2017 - 3:00pm
CHE (Chemed Corp.)
Wednesday, July 26 2017 - 2:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
FGEN (FibroGen, Inc.)
Tuesday, May 9 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
IMGN (ImmunoGen, Inc.)
Friday, May 5 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
EXEL (Exelixis, Inc.)
Monday, May 1 2017 - 9:00pm

AlphaGraphics you may like